<div id="readability-page-1">Vanda Pharmaceuticals Inc. ( VNDA ) on Monday released topline results from its randomized controlled clinical study (VP-VLY-686-2601) evaluating tradipitant to prevent nausea and vomiting induced by Novo Nordisk A/S ( NVO ) Wegovy. • Get the market research on VNDA stock here. The trial studied 116 healthy overweight or obese adults. The study saw 29.3% of tradipitant-treated participants (17/58) experience vomiting as compared to 58.6% on placebo (34/58), representing a 50% relative reduction. The study also met the key secondary endpoint of the proportion of participants with vomiting and significant nausea at 22.4% in the tradipitant group (13/58) versus 48.3% on placebo (28/58). Tradipitant demonstrated a favorable safety profile consistent with previous studies, with no new safety signals observed. Also Read: FDA Unveils Grounds For Rejecting Vanda Pharmaceuticals’ Stomach Paralysis Candidate <h2>Analyst Take</h2> B Riley, in an investor note on Tuesday, wrote, “While we believe this opens a potential blockbuster opportunity in GLP-1 supportive care that is not yet in our model, more immediately, it incrementally de-risks the pending motion sickness PDUFA (12/30/25). Combined with the bysanti 1Q26 PDUFA for schizophrenia and bipolar disorder that anchors the core investment thesis, analyst Madison El-Saadi views current valuation levels as increasingly disconnected from Vanda’s execution momentum and near-term catalyst density. B Riley reiterates a Buy rating and a price target of $11. H.C. Wainwright on Wednesday wrote that, “From our vantage point, these data appear robust and clinically meaningful. We draw investors’ attention to the fact that in this trial, patients were administered a very high dose of Wegovy without a titration period — this clearly set a high bar to overcome for tradipitant in attenuating the side effects of the drug.” Analyst Raghuram Selvaraju says that Vanda could partner with one of the current marketers of GLP-1 RA drugs for weight loss in order to optimize the value of tradipitant in the future. The analyst reiterates the Buy rating and a price target of $20. Jefferies analyst Andrew Tsai wrote that, “positioned as an adjunct therapy, tradipitant could potentially improve GLP-1’s relatively poor adherence (30%-50% discontinuation rates). We are curious how the benefits evolve upon longer dosing.” Jefferies has a Hold rating and a $5 price target. VNDA Price Action: Vanda Pharmaceuticals ( VNDA ) stock was down 4.97% at 4.88 on Thursday at publication. Read Next: <ul> <li>Tesla Rival BYD Could Bring Its Japanese ‘Kei’ Car To Europe</li> </ul> Photo: Shutterstock</div>

Vanda制藥

Vanda 製藥報告了關於 tradipitant 在預防與 Wegovy 相關的噁心和嘔吐方面的積極研究結果。分析師們持樂觀態度，B Riley 和 H.C. Wainwright 重申了買入評級，目標價分別為 11 美元和 20 美元。Jefferies 維持持有評級，目標價為 5 美元。研究顯示，與安慰劑相比，使用 tradipitant 的嘔吐減少了 50%。Vanda 的股票下跌了 4.97%，至 4.88 美元

Vanda 在 Wegovy 支持研究中取得重大勝利，分析師對此持樂觀態度